Trinity Biotech(TRIB)
icon
搜索文档
Trinity Biotech(TRIB) - 2024 Q3 - Earnings Call Transcript
2024-11-16 01:37
财务数据和关键指标变化 - 2024年Q3营收为1520万美元,较2023年Q3增长3% [37] - 2024年Q3毛利润为530万美元,毛利率为35%,与2023年可比季度(排除2023年包含的库存过时成本)大致一致 [39] - 2024年Q3研发费用较可比季度减少20万美元,本季度资本化210万美元 [40] - 2024年Q3销售管理费用为650万美元,较2023年Q3的770万美元大幅减少120万美元 [41] - 2024年Q3重组成本约为30万美元,年初至今总成本为230万美元,预计Q4还会有进一步成本产生 [42] - 2024年Q3净财务费用增加约20万美元 [43] - 2024年Q3调整后的EBITDASO为140万美元亏损,较去年同期350万美元亏损有所改善,基本每股美国存托凭证亏损0.46美元,较2023年Q3的0.88美元有所减少 [44] - 2024年Q3现金余额从6月30日的530万美元降至9月底的280万美元,运营使用现金360万美元,较2023年Q3改善100万美元,投资现金流出310万美元,融资活动现金流入420万美元 [45] 各条业务线数据和关键指标变化 - 2024年Q3即时检测业务营收增长60%至430万美元,其中TrinScreen产品销售额约为240万美元,重申2024年TrinScreen全年销售额约为1000万美元 [37] - 2024年Q3临床实验室营收为1080万美元,较2023年Q3下降9%,临床化学业务组合营收同比增长近80%,但血红蛋白业务营收同比下降70% [38] - 2024年Q3血红蛋白业务通过供应链举措和修订后的制造流程降低了制造成本,Trin Screen HIV销售目前稀释了整体毛利率,预计未来三个季度将逐步改善 [39] 各个市场数据和关键指标变化 - 糖尿病管理的连续血糖监测(CGM)市场每年价值超过100亿美元且预计快速增长 [6] - 前列腺癌诊断和治疗成本估计每年超过1000亿美元 [21] - 美国子痫前期影响多达5%的妊娠,败血症相关住院治疗的年度成本估计超过500亿美元 [23][25] 公司战略和发展方向和行业竞争 - 公司长期增长将由糖尿病管理的连续血糖监测(CGM)推动,正在设计下一代解决方案,以降低每日成本、捕捉更多生理数据点为目标,已成功完成首次关键前试验,本周开始第二次更大规模的试验,正与大规模高端市场参与者建立战略制造和供应链关系,且收到商业和战略合作伙伴的大量意向合作 [6][12][13][14][15][18][17] - 通过收购创新的前列腺癌和子痫前期检测技术以及对败血症诊断技术的战略投资来构建高增长潜力产品管线,前列腺癌的epiCaPture测试可减少不必要的干预,提高患者生活质量,子痫前期的Metabolomic Diagnostics的PrePsia技术可早期检测风险,公司将先以实验室开发测试的形式在美国提供服务,之后寻求FDA批准作为测试试剂盒销售,前列腺癌测试预计2026年产生营收,子痫前期测试预计2025年下半年产生营收 [7][19][21][22][23][24][55][57] - 公司继续推进全面转型计划,包括降低成本(如制造整合和离岸外包、优化供应链、集中和离岸公司服务等),目标是到2025年Q2实现约2000万美元的年化运行率息税折旧及股票期权成本前盈利(EBITDASO)和约7500万美元的年化运行率营收 [26][27][29][30][31][33] - 利用纽约州实验室吸引新技术和产品,结合自身能力解决大规模临床问题,以应对美国FDA对实验室开发测试(LDTs)规则的变化带来的机遇,在评估新机会时关注大规模疾病领域、差异化治疗路径的诊断以及下一代技术平台的利用 [19][20] 管理层对经营环境和未来前景的评论 - 公司在过去一年经历重大转型,目前正着眼于未来的增长驱动因素,尽管一些盈利举措尚未显著增加盈利能力,但预计年底或2025年初将实现盈利能力的阶跃变化,对公司在CGM、前列腺癌和子痫前期项目中的未来发展充满信心,同时也感谢股东、合作伙伴和员工在解决纳斯达克上市要求缺陷过程中的支持 [5][11][34][35] 其他重要信息 - 公司已重新符合纳斯达克上市要求,消除了股票的一个重要不利因素 [34] 问答环节所有的提问和回答 问题: 2024年Q4 TrinScreen的营收预期是否为略高于300万美元 - 回答: 是的,由于HIV快速检测销售的季度订单模式存在差异,且TrinScreen的订单规模通常比Uni - Gold大,预计Q4约为300万美元 [48] 问题: Premier Instruments业务在Q4或2025年是否会恢复,本季度销售额较低是否因为部分客户等待新产品推出 - 回答: 耗材的核心营收季度间大致稳定,本季度仪器放置销售减少主要是因为公司在推广新的产品方案,且进行了供应链变革以降低仪器成本,整体吞吐量和耗材营收稳定,这是一种暂时的减少 [49][50][51] 问题: 成本削减举措的第一阶段是否预计在2025年Q1末完成 - 回答: 是的,公司在高度监管的环境下运营,运营结构的改变需要大量规划和执行,预计这些改变将在Q4末或2025年初完成,届时将带来盈利能力和现金流的收益 [52][53][54] 问题: 前列腺癌和子痫前期测试的商业化时间表,是否将在美国全境销售 - 回答: 子痫前期测试预计2025年下半年产生营收,将先以实验室开发测试的形式在美国全境提供服务,之后寻求FDA批准作为测试试剂盒销售;前列腺癌测试预计2025年开始提供测试服务,2026年产生营收 [55][57] 问题: 由于这两项收购,Q4的股票数量预计是多少 - 回答: 目前没有这个数字,之后会回复 [58] 问题: 实现2025年Q2销售和EBITDA增长目标的两三个最重要的因素是什么 - 回答: 从三个美国工厂减少到一个将产生重大影响,将部分运营的较不复杂方面离岸外包给低成本地区的合作伙伴也有很大贡献,离岸和整合公司服务也有影响,虽然影响程度低于制造方面的基础设施变革,但有助于流程现代化、提高灵活性和扩展能力 [59][60] 问题: TrinScreen 2025年的营收主要来自新的招标还是基于现有招标的增长 - 回答: 两者都有,公司正在参与多个TrinScreen的评估流程,虽然招标和评估的时间不确定,但公司已证明能够按时高质量地供应大量产品,并且希望并预计在2025年赢得更多招标和评估 [61][62] 问题: 当前ATM(自动取款机)的剩余容量是多少 - 回答: 当前ATM备案中剩余不到100万 [63]
Trinity Biotech Announces Q3 2024 Financial Results
GlobeNewswire News Room· 2024-11-15 22:00
Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately $75 million by Q2 2025 Reiterates guidance to achieve 2024 sales revenue for TrinScreen HIV of approximately $10 million DUBLIN, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRI ...
Trinity Biotech to Announce Q3 2024 Financial Results
GlobeNewswire News Room· 2024-11-14 21:07
DUBLIN, Ireland, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the third quarter 2024 on Friday, November 15, 2024 and host a conference call at 10:00 AM ET. Conference Call Dial-In & Webcast Information Date:Friday, November 15, 2024Time:10:00 AM ETUnited States:1-877-407-0784International:1-201-689- ...
Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform
GlobeNewswire News Room· 2024-10-25 20:45
DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic investment in Novus Diagnostics, a company pioneering a rapid sepsis testing platform. This investment will accelerate the development and commercialization of Novus’ groundbreaking point-of-care diagnostic solutions, including its 15-minute bloodstream infection test. ...
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture
GlobeNewswire News Room· 2024-10-25 20:45
DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the acquisition of EpiCapture Limited, a company developing a non-invasive test for monitoring the risk of aggressive prostate cancer. This acquisition marks Trinity Biotech’s strategic expansion into the oncology diagnostics market. Prostate cancer is the most common non-skin canc ...
Trinity Biotech Shares Surge on Positive Pre-Pivotal Clinical CGM Trial
ZACKS· 2024-10-09 02:25
Trinity Biotech plc (TRIB) has completed its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor (CGM). This trial assessed the effectiveness of significant technology enhancements since acquiring the CGM from Waveform Technologies in January 2024. The results confirm the progress in improving performance, usability and cost-efficiency, positioning Trinity Biotech for further advancements. CGMs are wearable devices that track real-time glucose levels using biosensor ...
Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology
GlobeNewswire News Room· 2024-10-07 20:15
DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the successful completion of its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor (CGM) technology. The study assessed the analytical performance of CGM technology enhancements implemented by Trinity Biotech since acquiring the technolog ...
Trinity Biotech(TRIB) - 2024 Q2 - Quarterly Report
2024-10-02 23:22
Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Des Fitzgerald Eric Ribner (353)-1-2769800 (1)-646-751-4363 E-mail: investorrelations@trinitybiotech.com Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance -Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized revenues of approximately $75 million by Q2 2025- -Strong sequential 39% Q/Q growth on Point-of-Care revenues associated with successful rollout and sca ...
Trinity Biotech's Stock Rises After Acquisition of Metabolomics
ZACKS· 2024-09-25 23:45
Trinity Biotech plc (TRIB) has announced the acquisition of privately held Irish deep-tech company Metabolomics Diagnostics. The acquired company specializes in the development of novel biomarker-based diagnostic solutions for complex diseases and is likely to improve diagnostic accuracy using mass spectrometry and machine learning for Trinity Biotech. Trinity Biotech's deal values Metabolomics Diagnostics at approximately $1.3 million. Trinity Biotech will pay the amount with just over 270,000 Trinity Biot ...
Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market
GlobeNewswire News Room· 2024-09-25 04:05
-Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women- -The PrePsia test can predict preeclampsia risk as early as in the 12th week of pregnancy, allowing for early interventions to prevent serious health issues for mothers and their babies- -PrepSia will be commercialized in the U.S. market in 2025 through Trinity Biotech's New York-based Immco reference laboratory- D ...